Precision oncology is drawing some of the deepest pockets in biotech, and a young Seattle company just collected its own.
InduPro, which runs labs in Seattle and Cambridge, Massachusetts, announced a $77M Series B led by The Column Group. Vida Ventures, MRL Ventures Fund, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi and Eli Lilly and Company joined in.
The money arrives as the four-year-old company begins testing IDP-001, an antibody-drug conjugate built to hit cancer cells through a pairing of two surface proteins. A first patient has been dosed in a Phase 1 study enrolling adults with advanced or metastatic non-small cell lung cancer and other solid tumors that progressed past standard treatment.
InduPro’s ARRIS platform works from the spatial relationships between proteins on cell surfaces. The company believes target combinations that sit close together on cancer cells, but not on healthy tissue, let drugs attack tumors more selectively.
With pharma heavyweights on the cap table alongside VCs, the round reads as a wager that spatial biology can sharpen the next generation of cancer therapies.
